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ABSTRACT
Increasing evidence indicates that abnormal pain processing is present in the 
central nervous system of patients with Crohn’s disease (CD). The purposes of this 
study were to assess changes in gray matter (GM) volumes in CD patients in remission 
and to correlate structural changes in the brain with abdominal pain. We used a 
3.0 T magnetic resonance scanner to examine the GM structures in 21 CD patients 
with abdominal pain, 26 CD patients without abdominal pain, and 30 healthy control 
subjects (HCs). Voxel-based morphometric analyses were used to assess the brain 
GM volumes. Patients with abdominal pain exhibited higher CD activity index and 
lower inflammatory bowel disease questionnaire scores than those of the patients 
without abdominal pain. Compare to HCs and to patients without abdominal pain, 
patients with abdominal pain exhibited lower GM volumes in the insula and anterior 
cingulate cortex (ACC); whereas compare to HCs and to patients with abdominal pain, 
the patients without abdominal pain exhibited higher GM volumes in the hippocampal 
and parahippocampal cortex. The GM volumes in the insula and ACC were significantly 
negatively correlated with daily pain scores. These results suggest that differences 
exist in the brain GM volume between CD patients in remission with and without 
abdominal pain. The negative correlation between the GM volumes in the insula and 
ACC and the presence and severity of abdominal pain in CD suggests these structures 
are closely related to visceral pain processing.
INTRODUCTION
Abdominal pain is an important clinical 
manifestation of Crohn’s disease (CD). Such pain occurs 
not only in approximately 50% to 70% of patients during 
acute inflammation [1] but also in a significant proportion 
of patients during clinical and/or endoscopic remission 
[2]. Abdominal pain in patients with CD in remission 
has been associated with emotional suffering, disability, 
and high medical costs. Limited treatment options are 
currently available for this pain [3], and understanding the 
neurophysiological underpinnings of pain is fundamental 
to the development of an effective treatment.
The pathophysiology of abdominal pain in patients 
with CD in clinical remission is multifaceted. In these 
patients, pain is related to a dysfunction in brain-gut 
interactions [4], low-grade intestinal inflammation 
[5], visceral hypersensitivity [6], and other related 
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mechanisms. The sensitization of the central nervous 
system (CNS) and reorganization of brain areas might play 
a role in visceral pain processing in CD [3, 7]. Magnetic 
resonance imaging (MRI) has been used to assess the 
structural plasticity and reorganization of the brain under 
different pathological conditions. Previous MRI studies 
have demonstrated pain-related cortical changes in 
patients with chronic conditions, such as irritable bowel 
syndrome [8, 9], chronic pancreatitis [10], and trigeminal 
neuropathic pain [11]. To date, several studies [12–14] 
have demonstrated structural changes in gray matter 
(GM) in patients with CD. The GM volume [12], sub-
cortical volume [13], cortical thickness [12–14], surface 
area [13, 14]and folding [14] of multiple brain regions 
were significant changed. In our previous study [12], we 
found that, compare with healthy controls (HCs), patients 
with CD showed significant changes in GM volumes of 
multiple brain regions involved in pain, emotion, and 
homeostasis, and specific altered profiles of GM volume 
correlated with disease duration. Although these studies 
revealed changes in the GM structures in various brain 
regions, and pain has been associated with GM loss in 
numerous studies, the specific patterns of altered GM in 
patients with CD with or without abdominal pain have yet 
to be delineated.
In this study, we hypothesized that the structural 
changes in GM vary between patients with and without 
abdominal pain and that sustained abdominal pain is 
associated with changes in brain GM in areas involved 
in visceral pain processing. Specifically, the aims of the 
study were (1) to determine the changes in GM volume 
in patients with and without abdominal pain and (2) to 
potentially correlate the GM structural changes in specific 
brain regions with pain severity. 
RESULTS
HCs vs. patients with CD with or without 
abdominal pain
Clinical variables
Among the 47 quiescent patients, 21 (44.7%) 
experienced abdominal pain. The average pain score 
ranged from 1 to 5.4, with a mean ± standard deviation 
of 2.68 ± 1.18.
There were no significant differences among 
the three groups in gender, age, height or weight. No 
differences existed between the pain and pain-free CD 
groups in disease duration, Montreal classification, or 
concomitant medication. The anxiety and depression 
scores of Hospital Anxiety and Depression Scale (HADS; 
including HADS-A and HADS-D subscales) in the pain, 
pain-free and HC groups were significantly different 
(P < 0.01). The patients in the pain group had higher 
HADS-A and HADS-D scores than did the subjects in 
the HC group (P < 0.01). The patients in the pain-free 
group had higher HADS-A scores than those in the HC 
group (P  < 0.05). No significant difference was observed 
between the pain group and the pain-free group. The 
patients with abdominal pain exhibited higher CD activity 
index (CDAI) scores and lower Inflammatory Bowel 
Disease Questionnaire (IBDQ) scores than those of the 
patients without abdominal pain (P < 0.01). 
The platelet (PLT) level and erythrocyte 
sedimentation rate (ESR) were not significantly different 
between the pain group and the pain-free group, while the 
C-reactive protein (CRP) level was significantly different 
between these two groups (P < 0.01). The Crohn’s disease 
endoscopic index of severity (CDEIS) scores of all the 
patients were below 3, with a mean (min~max) value of 
1.24 (0~2.6) for the pain group and 0.89 (0~2.0) for the 
pain-free group. No significant difference was observed 
between the two groups (Table 1).
The CDAI scores of all the patients were correlated 
with the CDEIS scores (r = 0.445, P < 0.01), CRP levels 
(r = 0.361, P < 0.05), PLT levels (r = 0.407, P < 0.01), and 
ESR levels (r = 0.431, P < 0.01). 
Differences in GM volume
A one-way ANOVA revealed that the GM volumes 
of 4 brain regions, including the left insula, hippocampal 
and parahippocampal cortex (HIPP/paraHIPP) and 
putamen, and right anterior cingulate cortex (ACC) 
(Table  2, Figure 1A), were significantly different among 
the pain, pain-free, and HC groups.
The post-hoc analysis showed that the GM volumes 
of the insula and ACC in the pain group were lower 
than those in the pain-free and the HC groups. The GM 
volumes of the HIPP/paraHIPP in the pain-free group 
were higher than those in the pain and HC groups. The 
GM volumes of the putamen in the pain and pain-free CD 
groups were higher than those in the HC group; however, 
the difference between the two patient groups was not 
significant (Table 3, Figure 1B).
These results suggested that the patients with CD-
related abdominal pain yielded the lowest GM volumes 
in the insula and ACC whereas the CD patients without 
abdominal pain exhibited the highest GM volumes in the 
HIPP/paraHIPP.
Correlation between GM volumes and the 
severity of abdominal pain
The GM volumes of the insula and ACC were 
significantly negatively correlated with the daily pain 
scores in the patients with abdominal pain (r = -0.64, 
P = 0.002; r = -0.69, P = 0.001, respectively; Figure 1C). 
The GM volumes in the HIPP/paraHIPP of the CD patients 
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with abdominal pain were not significantly correlated with 
the daily pain scores (r = -0.30, P = 0.18). 
For the whole-brain analysis, the daily pain scores 
negatively correlated with the GM volumes of the right 
ACC, left OFC and bilateral insula (Table 4, Figure 2).
DISCUSSION
In the present study, we found the lowest GM volumes 
in the insula and ACC in remissive CD patients with 
abdominal pain. The reduced GM volumes in the insula 
Table 1: Clinical demographics of the CD with pain, pain-free CD, and HC groups
CD with Pain 
(n = 21)
Pain-free CD
(n = 26)
HC
(n = 30) P value
Gender (male/female) 12/9 20/6 20/10 0.352
Age (years) 30.86 ± 6.99 29.77 ± 7.23 30.47 ± 5.93 0.850
Height (cm) 169.33 ± 8.71 170.69 ± 5.96 169.60 ± 7.68 0.794
Weight (kg) 55.88 ± 9.66 57.62 ± 9.37 59.10 ± 6.47 0.410
HADS-A 6.52 ± 3.75** 5.27 ± 2.66* 3.40 ± 2.01 0.001
HADS-D 5.90 ± 3.99** 3.65 ± 2.87 3.00 ± 1.72 0.002
Disease duration (months) 88.29 ± 52.76 68.77 ± 45.04 — 0.178
CDAI 93.86 ± 36.00### 44.52 ± 30.74 — 0.000
IBDQ 162.95 ± 29.74## 187.77 ± 18.76 — 0.003
PLT 229.81 ± 33.00 209.00 ± 49.63 — 0.106
ESR 12.37 ± 5.10 9.85 ± 5.70 — 0.123
CRP 5.46 ± 2.35## 2.92 ± 2.72 — 0.002
CDEIS 1.24 ± 0.76 0.89 ± 0.50 — 0.068
Montreal classificationΔ
Age at diagnosis
A1 0 4 —
0.074A2 20 22 —
A3 1 0 —
Location
L1 3 7 —
0.606
L2 4 5 —
L3 14 14 —
L4 0 0 —
Behavior
B1 7 9 —
0.385
B2 1 2 —
B3 6 7 —
B1P 0 4 —
B2P 1 0 —
B3P 6 4 —
Concomitant medication 15 15 —
5-Aminosalicylate 9 7 —
0.240
Azathioprine 3 7 —
5-Aminosalicylate & 
azathioprine
3 1 —
*P < 0.05 and **P < 0.01 compared with the HC group; ##P < 0.01 and ###P < 0.001, compared with the pain-free group; 
Δ Montreal classification: A1, below 16 years; A2, between 17-40 years; A3, above 40 years; L1, ileal; L2, colonic; L3, 
ileocolonic; L4, isolated upper disease; B1, non-stricturing, non-penetrating; B2, structuring; B3, penetrating; P, perianal 
disease modifier. CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CDEIS, Crohn’s disease endoscopic index of 
severity; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HADS-A, Hospital Anxiety and Depression Scale 
anxiety score; HADS-D, Hospital Anxiety and Depression Scale depression score; HCs, healthy controls; IBDQ, Inflammatory 
Bowel Disease Questionnaire; PLT, platelet. Values are presented as the mean values (standard deviations).
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and ACC were correlated with the daily pain scores of the 
patients. The patients without abdominal pain exhibited the 
highest GM volumes in the HIPP/paraHIPP. These findings 
suggested that the structural reorganization of the brain 
varied between CD patients with abdominal pain and those 
without pain, which may indicate a relationship between 
changes in specific brain structures and the existence of 
visceral pain in patients with intestinal inflammatory disease.
Similar to the observations in the patients with 
CD-related abdominal pain, abnormal changes in GM 
structures in the insula and ACC occur in patients afflicted 
with other chronic diseases such as lower back pain [15], 
irritable bowel syndrome [9] and fibromyalgia [16] and 
also similar to functional activity changes in these CD 
patients reported in our previous study [17]. These brain 
areas are important components of pain networks [18, 
19]. The ACC and insula are the key components of the 
medial pain system, which might be primarily involved in 
processing affective-motivational aspects of pain. Studies 
[20, 21] have shown that the ACC is not only involved 
in the transmission of pain sensations but also plays a 
role in processing pain-related emotion. The ACC might 
respond to pain and participate in pain control [20]. The 
insula participates in the integration of visceral sensation 
and motor function and is responsible for transmitting pain 
signals to the frontal cortex [10]. 
Figure 1: Significant differences in GM volumes in patients with CD-related pain, CD without pain, and HC groups 
with total GM volume, age, gender, weight, anxiety and depression as covariates. (A) GM volumes of the putamen, HIPP/
paraHIPP, insula and ACC differed significantly among the 3 groups. (B) Post-hoc analysis showed that the GM volumes of the insula and 
ACC in the CD with pain group were lower than the GM volumes in the remaining two groups. The GM volumes of the HIPP/paraHIPP in 
the pain-free group were higher than the GM volumes in the remaining two groups. The GM volumes of the putamen in the HC group were 
lower than the GM volumes in the remaining two groups, but the CD with pain and pain-free CD groups were not significantly different. (C) 
Correlation analysis between the GM volumes of the ROIs in the CD with pain group and the pain scores. ACC, anterior cingulate cortex; 
CD, Crohn’s disease; HC, healthy controls; HIPP/paraHIPP, hippocampal and parahippocampal cortex; L, left hemisphere; r, correlation 
coefficient; ROI, region of interest; VAS, visual analogue scale; *P  < 0.05, **P < 0.01, ***P < 0.005. 
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The visceral pain (abdominal pain) signals may 
be transmitted to the "visceral and cortical pain matrix" 
via the brain - gut axis in CD patients [3]. Specifically, 
pain fibers carrying visceral nociceptive signals from 
the periphery synapse traverse through unmyelinated C 
fibers on both sides of the spinal cord to the dorsal root 
ganglia of spinal afferent nerves and synapse onto dorsal 
horn neurons and then ascend to the higher order brain 
processing areas in the thalamic nuclei and reticular 
formation [3]. The thalamic nuclei project to the primary 
and secondary somatosensory cortex where the sensory-
discriminative aspects of pain is processed, and the 
reticular formation projects to the limbic system and 
frontal cortex, where the affective-motivational aspects of 
pain is processed [3, 20]. In this way, visceral pain signals 
in CD patients may be mainly transmitted to ACC and 
insula of the limbic system via the reticular formation. 
We found that the GM volumes in the insula and 
ACC were negatively correlated with the daily pain 
scores in the patients with abdominal pain. The whole-
brain analysis further confirmed the correlation and 
increased the reliability of the study. Structural GM 
abnormalities in the insula and ACC have been observed 
in nearly all pain-related diseases [22]. Similar negative 
correlations between GM volume and pain severity have 
also been observed in other imaging studies on GM 
plasticity, such as post-herpetic neuralgia, chronic back 
pain, and osteoarthritis [23]. The pain in CD patients in 
clinical remission is chronic, involves multiple factors. 
CD patients with abdominal pain yielded higher disease 
Table 2: Brain regions with significant differences in GM volume among the CD with pain, pain-
free CD, and HC groups
Regions Hem BA
MNI
F value Voxels
X Y Z
ACC R 32 3 51 15 7.98 151
Insula L 47 39 21 3 9.61 137
HIPP/paraHIPP L 28 -18 –6 -24 10.09 178
Putamen L 11 -24 15 -3 17.56 417
The results were based on the total GM volume, age, gender, weight, anxiety and depression as covariates. The statistical 
threshold was set at P < 0.05, and the false discovery rate was corrected for multiple comparisons. ACC, anterior cingulate 
cortex; CD, Crohn’s disease; HC, healthy controls; HIPP/paraHIPP, hippocampal and parahippocampal cortex; L, left 
hemisphere; R, right hemisphere.
Figure 2: Brain regions with significant correlation between the GM volumes and daily pain scores in CD patients with 
abdominal pain using whole-brain correlation analysis. The daily pain scores correlated negatively with the GM volumes of the 
right ACC, left OFC, and bilateral insula.
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condition indices (CDAI scores and CRP levels) and 
significantly lower quality of life (QOL) than patients 
without abdominal pain, suggesting that the pain may not 
only be involved in the afferent processing of visceral pain 
signals, but may also be related to the stimulation of low 
inflammation in peripheral circulation. 
In general, the mechanism underlying GM changes 
may be attributed to frequent and chronic nociceptive 
input and the subsequent functional reorganization and 
plasticity of the brain. The lower GM volumes could 
be related to a decrease in the size of neuronal somata, 
cell atrophy, or a decrease in intra-cortical axonal 
architecture (i.e., synaptic loss) [24]. In addition to the 
afferent processing of visceral pain signals, circulating 
inflammatory cytokines/mediators can reach the brain 
through circumventricular organs and active transport 
[25, 26], which may promote GM changes by inducing 
the apoptosis of neural or glial cells, including astrocytes 
and oligodendrocytes [27, 28], and activating endothelial 
cells, microglial cells, and macrophages. Furthermore, 
inflammatory cytokines/mediators may propagate signals 
within the brain by suppressing neurogenesis and exerting 
cytotoxic effects via increased glutamatergic activation 
and increased oxidative stress [28]. Thus, interactions 
among chronic nociceptive input, inflammation-induced 
neuronal changes, and brain reorganization may contribute 
to the reduced GM volumes in brain regions that are 
observed during pain processing and perception. 
The patients without CD-related pain exhibited 
the highest GM volumes in the HIPP/paraHIPP, while 
the patients with CD-related pain exhibited lower GM 
volumes in this region. These findings suggest a role for 
specific brain structures in the control of abdominal pain 
in this disease: patients with the highest GM volumes 
exhibited better intrinsic pain relief (CD without pain) 
than patients with a lesser GM volumes increase (CD 
with pain). The HIPP/paraHIPP is associated with limbic 
and non-limbic system structures; the HIPP/paraHIPP 
regulates immune responses via the hypothalamic-
pituitary-adrenal axis and neurohumoral pathways and 
plays an important role in neural immune regulation 
[29]. Studies have shown that experimental colitis and 
intestinal dysbiosis are associated with aberrant mRNA 
or protein expression of brain-derived neurotrophic factor 
in the HIPP/paraHIPP and the abnormal development of 
anxiety-like behavior [30]. The HIPP/paraHIPP may also 
interact with the vagus nerve, which is involved in the 
neural modulation of intestinal inflammation by releasing 
acetylcholine to regulate the functions of immune cells in 
the intestinal wall. In addition, an abnormal blood oxygen 
level-dependent (BOLD) signal has been found in the 
HIPP/paraHIPP in inflammatory bowel disease patients 
relative to control subjects [31]. Furthermore, given the 
critical role of the HIPP/paraHIPP in pain processing 
and modulation [32] and the finding that the highest GM 
volumes were present in the patients without abdominal 
Table 3: The post-hoc analysis of the GM volume in the brain regions with significant differences 
among the CD with pain, pain-free CD, and HC groups
Regions CD with pain (n = 21)
Pain-free 
CD (n = 26) HC (n = 30)
Pain vs. pain-free Pain vs. HC Pain-free vs. HC
Effect size P value Effect size P value Effect size P value
ACC_R 0.56 ± 0.15 0.67 ± 0.19 0.70 ± 0.14 0.64 0.02 0.96 0.002 0.18 0.432
Insula_L 0.75 ± 0.09 0.83 ± 0.10 0.85 ± 0.10 0.84 0.009 1.05 0.001 0.20 0.417
HIPP/
paraHIPP_L
1.04 ± 0.10 1.10 ± 0.10 1.02 ± 0.08 0.70 0.018 0.22 0.295 1.06 0.000
Putamen_L 0.98 ± 0.15 1.00 ± 0.11 0.87± 0.12 0.15 0.619 0.81 0.003 1.13 0.000
Data are present as mean ± SD. ACC, anterior cingulate cortex; CD, Crohn’s disease; HC, healthy controls; HIPP/paraHIPP, 
hippocampal and parahippocampal cortex; L, left hemisphere; R, right hemisphere.
Table 4: Whole-brain correlation analysis between the GM volumes and daily pain scores in CD 
patients with abdominal pain
Regions Hem BA
MNI
T Value Voxels
X Y Z
ACC R 11 3 36 –3 –4.37 127
Insula R 47 41 24 0 –4.86 134
Insula L 47 –38 21 0 –5.56 120
OFC L 11 –3 58 –9 –5.33 123
The results employed age, gender, weight, anxiety and depression as covariates. The statistical threshold was set at P < 0.005 
(uncorrected) and cluster P < 0.05 (false discovery rate corrected). ACC, anterior cingulated cortex; BA, Brodmann area; Hem, 
hemisphere; L, left; OFC, orbitofrontal cortex; R, right. 
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pain may suggest an enhanced compensation by this 
region. 
The present study has two limitations. First, this 
study was a cross-sectional study, which prevented the 
confirmation of a relationship between the abnormal GM 
changes in the CD patients in remission with the disease 
onset or the disease per se. In addition, neurotransmitter 
modulation and receptor binding in the associated brain 
areas and the correlation of these parameters with the GM 
structural changes must be elucidated. Future studies should 
observe longitudinal brain GM changes, together with the 
levels of related neurotransmitters in target brain regions, 
and to elucidate the neuroimaging biomarkers of CD. 
In summary, our study represents the first 
investigation to demonstrate differences in brain GM 
volumes between CD patients in remission with and 
without abdominal pain. The reduced GM volumes in 
the insula and ACC in patients with CD with abdominal 
pain suggest a potential role in visceral pain processing 
and correlate with the presence and severity of abdominal 
pain. The findings may expand our understanding of the 
pathogenesis of CD, particularly the pathophysiology 
underlying pain in patients with CD.
MATERIALS AND METHODS
Subjects
All participants provided written informed consent. 
The study protocol was approved by the Institutional 
Review Board of Yueyang Hospital of Integrated 
Traditional Chinese and Western Medicine at Shanghai 
University of Traditional Chinese Medicine.
This study evaluated 21 patients with CD-related 
abdominal pain, 26 CD patients without abdominal pain, 
and 30 HCs. All the patients underwent a systemic and 
gastrointestinal examination, including a colonoscopy 
and pathological tissue biopsy. Laboratory tests and the 
colonoscopy were performed at 2 weeks and 1 month 
before the MRI scan, respectively. The CRP level, ESR, 
and PLT level were measured in all the patients. For the 
endoscopic examination, the CDEIS scores [33] were 
scored by an experienced endoscopist who was blinded to 
other details of the patients with CD. 
The HCs were recruited via advertisements from 
Shanghai University of Traditional Chinese Medicine. 
These subjects were not treated with any medications, had 
no gastrointestinal symptoms or pain-related diseases, nor 
had negative findings in colonoscopic examinations.
Eligibility criteria
The inclusion criteria were as follows: aged 
between 18 and 50 years, ≥ 6 years of education, right-
handed, a CDAI of < 150, a CDEIS score of < 3 and 
in disease remission for > 12 months. Patients were 
excluded from the study if they met any of the following 
conditions: elevated biological disease activity indices 
(CRP > 10 mg/L, ESR > 20 mm/h, PLT > 300×109/L); a 
history of CD-related abdominal surgery; treatment with 
corticosteroids, biological agents, psychotropic or opioid 
drugs in the previous 3 months; pregnant or lactating; 
a current or past history of psychiatric or neurological 
disorders, head trauma or loss of consciousness; 
claustrophobic; or had metal implants.
Furthermore, CD patients with chronic abdominal 
pain (i.e., dull periumbilical pain and/or pain in the right/
left lower quadrant, etc. for ≥ 3 days per week for at least 
12 months) were included in the pain group. Patients 
without abdominal pain for at least 12 months were 
included in the pain-free group.
Symptoms and psychological assessment
The intensity of abdominal pain in the CD patients 
was evaluated using a 0-10 visual analog scale (VAS) [34]. 
The average pain score was calculated by dividing the 
total pain score by the number of days of pain during the 
week prior to the MRI scan. The CDAI [35] and the IBDQ 
[36] were used to evaluate the patients’ disease conditions 
and QOL, respectively. 
The HADS [37] was used to assess the 
psychological status, including anxiety and depression, 
of all the subjects. The HADS included 14 questionnaire 
items and 7 items for each of the two sub-scales (anxiety 
and depression). Each item had a 4-point Likert scale (0-3 
points) and a sub-scale of more than 8 points indicating 
anxiety or depression.
Image acquisition
The MRI data were acquired in an interleaved 
multi-slice mode using a Siemens TRIO 3T clinical 
scanner (Magnetom Verio, Siemens, Erlangen, Germany). 
A high-resolution T1-weighted sagittal 3-dimensional 
magnetization-prepared rapid gradient-echo sequence 
was acquired for each participant with the following 
parameters: TR = 2300 ms; TE = 2.98 ms; field of view 
= 256 × 256 mm; matrix size = 256 × 256; in-plane 
resolution = 1 mm × 1 mm; slice thickness = 1.0 mm; flip 
angle = 9°; and slices = 176.
Image analysis
Voxel-based morphometry (VBM) preprocessing
Structural image processing and analysis were 
performed using optimized VBM8 toolbox (C. Gaser, 
Department of Psychiatry, University of Jena, Germany; 
http://dbm.neuro.uni-jena.de/vbm8) in the Statistical 
Parametric Mapping software, version 12 (SPM12; 
Wellcome Trust Centre for Neuroimaging, University 
College London, England; http://www.fil.ion.ucl.ac.uk/
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spm), which was operated in a MATLAB (Mathworks, 
Natick, MA, USA) environment. All the structural images 
were transformed into a Montreal Neurological Institute 
(MNI) 152 standard space using linear transformations 
re-sampled to 1.5 × 1.5 × 1.5 mm3. The images were 
subsequently segmented into GM, white matter (WM), 
and cerebrospinal fluid (CSF). A modulation step was 
added to incorporate volume changes during spatial 
normalization [38]. This step involved multiplying each 
spatially normalized GM image by the relative volume of 
the image before and after normalization. The resulting 
GM images were smoothed with an 8-mm full-width-at-
half-maximum (FWHM) isotropic Gaussian kernel.
Statistical analysis
At the secondary level of analysis, we determined 
the differences in the GM volumes among the HCs and 
the patients with or without pain. A one-way analysis of 
variance (ANOVA) was performed at each voxel to assess 
the main effect, with a statistical threshold was set at P < 
0.005 (uncorrected) and cluster P < 0.05 [false discovery 
rate (FDR) corrected]. The total GM volume, age, gender, 
weight, anxiety and depression were used as covariates. 
 For post hoc tests, regions of interest (ROIs) were 
selected from the sets of voxels within 6-mm spheres, with 
the centers at the peaks of the clusters with significant 
differences based on the ANOVA results of the VBM 
between the patients and the HCs. A 2-step correlation 
analysis was conducted in CD patients with abdominal 
pain: first, a Pearson’s correlation analysis was used to 
examine the relationship between the mean GM volume 
in each ROI and the pain score for the CD patients, with 
the total GM volume, age, gender, weight, anxiety and 
depression as covariates. The significance level was set at 
P < 0.05 with Bonferroni’s correction. Second, whole-brain 
correlation analysis was applied to determine potential 
correlations between the brain regions and pain condition. 
The significance level was set at P < 0.005 (uncorrected), 
and the FDR was corrected with the cluster size at P < 0.05.
The imaging results were overlaid on MRIcroN 
(http://www.sph.s.c.edu/comd/rorden/mricro.html) for 
presentation. The behavioral data were presented as the 
means ± standard deviations. The Statistical Package 
for the Social Sciences (SPSS) software package (SPSS 
Inc., Chicago, IL, USA), version 16.0, was used for the 
statistical analysis. 
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